Phosphoramidate PSMA Small-Molecule Conjugates for Reduced Off-Target Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for metastatic castration-resistant prostate cancer (mCRPC) face challenges such as off-target toxicity, immunogenicity, and high manufacturing costs associated with radiopharmaceuticals, necessitating the development of more effective and cost-efficient PSMA-targeted chemotherapeutics.
Innovation Solution
Development of small molecule-drug conjugates (SMDCs) that utilize PSMA-targeting motifs, acid-cleavable linkers, and potent cytotoxic payloads, which internalize in endosomes for controlled release of therapeutic agents, reducing off-target toxicity and manufacturing costs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibody-drug conjugates (ADCs) are used for PSMA-targeted therapy, then therapeutic efficacy is improved, but manufacturing costs and device complexity increase
Solution Approach 1:
The patent uses small-molecule PSMA inhibitors as simplified copies of the antibody targeting mechanism, retaining the essential function of PSMA binding and internalization while eliminating the complex antibody structure. This copying approach maintains therapeutic efficacy through accurate tumor localization while dramatically reducing manufacturing complexity and cost associated with producing antibody-based ADCs
Solution Approach 2:
The patent employs small-molecule inhibitors with shorter residence times that can be rapidly cleared from the system, replacing the need for expensive, long-lived antibody conjugates. These smaller molecules are more cost-effective to manufacture and can be administered at higher doses due to their shorter half-lives and lower immunogenicity, directly addressing the manufacturing cost and complexity issues
2Reliability
If radiopharmaceuticals are used for PSMA-targeted therapy, then therapeutic efficacy is improved, but off-target toxicity and handling complexity increase
Solution Approach 1:
The patent changes the key parameter of residence time by using small-molecule inhibitors with shorter half-lives compared to radiopharmaceuticals. This parameter change allows the drug to be cleared more rapidly from non-target tissues, reducing off-target toxicity while maintaining effective concentrations at the tumor site during the therapeutic window
Solution Approach 2:
The patent extracts the radioactive component from the therapeutic system, replacing radiopharmaceuticals with non-radioactive small-molecule drug conjugates. This extraction eliminates the handling complexity and safety concerns associated with radioactive materials while preserving the core mechanism of PSMA-targeted delivery and intracellular payload release
3Ease of manufacture
If small-molecule inhibitors are used instead of ADCs, then manufacturing cost and flexibility are improved, but molecular weight and diffusion characteristics change
Solution Approach 1:
The patent leverages the dynamic diffusion characteristics of small molecules, which can rapidly penetrate and distribute throughout tumor tissue due to their low molecular weight. This dynamic behavior allows the drugs to reach target cells more quickly and uniformly compared to larger ADCs, compensating for the smaller size through enhanced tissue penetration and distribution kinetics
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
SMDCs demonstrate accurate localization to prostate cancer lesions with lower toxicity and manufacturing costs, offering improved therapeutic efficacy and flexibility in dose regimen compared to conventional ADCs.
Implementation Method 1
an acid-cleavable linker L
Data Source
AI summary
The present invention relates to small molecules having high affinity and specificity to prostrate-specific membrane antigen (PSMA) and methods of using them for therapeutic and diagnostic purposes.